OPGN: צמיחת רווחי EPS רבעונית OpGen
OpGen, Inc. is experiencing an acute efficiency crisis, selling off patents to settle its obligations. This quarterly EPS trend clearly demonstrates this decline, where the 0.00 mark characterizes the current profit level. The business relies on the sale of Acuitas molecular tests, and cash flows depend on the adoption rate of diagnostic systems in clinics.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_OPGN_-_OpGen-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "OpGen (OPGN): צמיחת רווחי EPS רבעונית מ-04.07.2022 עד 31.08.2024 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור OpGen Corporation (OPGN)
The total loss of OpGen, Inc. (OPGN) positions in molecular diagnostics and a prolonged solvency crisis make the calculation of net income per share a critical indicator of business survival. This metric captures the percentage change in profit per quarter, reflecting the company's ability to generate income, which, in the dynamics of quarterly EPS, allows for the timely detection of regulatory risks and a dangerous contraction of capital.
